FDA Advisory Committee recommends PT027 in asthma
9 November 2022 07:00 GMT PT027 recommended by FDA advisory committee as new rescue treatment for asthma First and only rescue medication recommended for US approval that has been shown to reduce severe exacerbations The Food and Drug Administration's (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) has voted 16 to 1 that the data support a favourable benefit risk assessment for the use of PT027 (albuterol/budesonide) for the treatment of asthma in people aged 18 years and older. In adolescents aged 12 to 17 years, the Committee voted 9 to 8 that the data do not support a